Table 1.

Patent-expiration dates of biologics and development status for some biosimilars⁶⁴,⁸⁶–⁹³

Biologic	US patent expiration	Biosimilar status	EU patent expiration	Biosimilar status
Filgrastim	2013	Approved	2006	Approved
Epoetin-α	2015	Application filed	2004	Approved
Pegfilgrastim	2015	Application filed	2015	Application filed
Adalimumab	2016	Approved	2018	Approved
Rituximab	2018	Phase III trials	2013	Approved
Infliximab	2018	Approved	2015	Approved
Trastuzumab	2019	Application filed	2014	Application filed
Bevacizumab	2019	Application filed	2018	Application filed
Etanercept	2028/2029	Approved	2015	Approved

Notes: Expiration dates are based on those cited within Genetic Engineering & Biotechnology News,⁸⁸ although other patent dates may apply; there is no patent that specifically claims the composition of matter of cetuximab.